Reviva Pharmaceuticals Holdings Inc. (RVPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Reviva Pharmaceuticals Holdings Inc. (RVPH) has a cash flow conversion efficiency ratio of -0.389x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.92 Trillion) by net assets ($15.21 Trillion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Reviva Pharmaceuticals Holdings Inc. market cap and net worth for the company's overall valuation and market capitalisation.
Reviva Pharmaceuticals Holdings Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Reviva Pharmaceuticals Holdings Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Reviva Pharmaceuticals Holdings Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Reviva Pharmaceuticals Holdings Inc. ranked by their cash flow conversion efficiency. Explore Reviva Pharmaceuticals Holdings Inc. cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NEPRA FOODS INC.
F:2P6
|
N/A |
|
Heliospectra publ AB
ST:HELIO
|
-1.246x |
|
Truscott Mining Corporation Ltd
AU:TRM
|
-0.049x |
|
DGA Spólka Akcyjna
WAR:DGA
|
-0.053x |
|
The North American Income Trust plc
LSE:NAIT
|
0.019x |
|
Tennant Minerals Ltd
AU:TMS
|
0.011x |
|
Bloomsbury Publishing Plc
LSE:BMY
|
0.183x |
|
Woodlandor Holdings Bhd
KLSE:7025
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Reviva Pharmaceuticals Holdings Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of Reviva Pharmaceuticals Holdings Inc. from 2018 to 2025. View Reviva Pharmaceuticals Holdings Inc. stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $8.65 Million | $-24.59 Million | -2.844x | +93.11% |
| 2024-12-31 | $812.57K | $-33.54 Million | -41.281x | -733.47% |
| 2023-12-31 | $5.72 Million | $-28.32 Million | -4.953x | -119.28% |
| 2022-12-31 | $8.39 Million | $-18.96 Million | -2.259x | -507.36% |
| 2021-12-31 | $28.69 Million | $-10.67 Million | -0.372x | +50.01% |
| 2020-12-31 | $5.47 Million | $-4.07 Million | -0.744x | -2419.97% |
| 2019-12-31 | $-6.81 Million | $-218.44K | 0.032x | +277.08% |
| 2018-12-31 | $59.16 Million | $-1.07 Million | -0.018x | -- |
About Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, s… Read more